

List of Figures

List of Tables

Abbreviations

Preface

Chapters	Page No.
1 Introduction.....	1
2 Literature Review	8
2.1 Lung Cancer biology and its classification	8
2.2 Therapeutic options for treatment and diagnosis of lung cancer	10
2.3 Nanotherapeutic interventions in the treatment of lung cancer.....	14
2.4 Influence of the properties of the nanocarriers on lung cancer therapy	16
2.5 Nanotechnology in the diagnosis of lung cancer	17
2.6 Use of nanocarriers for the treatment of lung cancer	19
2.6.1 Lipid-based nanocarriers.....	20
2.6.2 Metallic nanocarriers.....	23
2.6.3 Magnetic nanocarriers.....	25
2.6.4 Polymer-based nanocarriers.....	27
2.7 Chitosan based Nano particulate system.....	33
2.7.1 Chitosan-sodium tripolyphosphate particulate system.....	33
2.7.2 Chitosan polyelectrolyte complexes	34
2.7.3 Surface modification of Chitosan particulate systems	34
2.8 Techniques for preparation of chitosan nanoparticles (CSN-NPs).....	34
2.8.1 Emulsion cross-linking method	35
2.8.2 Spray-drying	35
2.8.3 Emulsion droplet coalescence method.....	35
2.8.4 Nanoprecipitation.....	35
2.8.5 Reverse micellization method.....	36
2.8.6 Desolvation/simple coacervation/phase separation.....	36
2.8.7 Emulsion solvent diffusion	36
2.8.8 Ionic gelation	37
2.9 Excipients profile	37
2.9.1 Chitosan	37
2.9.2 Sodium Tripoly-phosphate.....	39
2.10 Targeting Ligands Profile	39
2.10.1 Sialic acid.....	40
2.10.2 Cetuximab	42

2.11	Drug Profile	44
2.11.1	Gemcitabine	44
2.12	Nanomedicine system suited for parenteral administration	49
2.13	Stability of nanomedicine	49
3	Glycan receptor targeted chitosan nanoparticles for targeted delivery of gemcitabine for lung cancer treatment.....	50
3.1	Objective	50
3.2	Plan of study	50
3.3	Materials	51
3.4	Methods.....	52
3.4.1	HPLC analytical & bioanalytical method development and validation	52
3.4.2	Experimental design for Optimization of chitosan nanoparticles	52
3.4.3	Formulation of GMC encapsulated non-targeted and targeted nanoparticles	54
3.4.4	Characterization of chitosan nanoparticles and 5-N-acetyl-neuraminic-acid conjugated chitosan nanoparticles	57
3.4.5	HPLC method for analysis of GMC.....	59
3.4.6	Entrapment efficiency of gemcitabine and <i>in vitro</i> drug release study.....	59
3.4.7	Cellular uptake	59
3.4.8	Cytotoxicity study	60
3.4.9	Animal Ethics.....	61
3.4.10	Development (induction) of Lung cancer	61
3.4.11	Tissue bio-distribution study.....	61
3.4.12	<i>In vivo</i> fluorescent imaging.....	62
3.4.13	Histopathology	62
3.4.14	<i>In vivo</i> anti-cancer efficacy	62
3.4.15	Statistical Data analysis	63
3.5	Results and Discussion	63
3.5.1	Analytical and bio-analytical HPLC method validation	63
3.5.2	Design of experiments (DOE) for optimization of chitosan nanoparticles	68
3.5.3	Optimization and validation of nanoformulations	72
3.5.4	Characterization of chitosan nanoparticles and 5-N-acetyl-neuraminic acid conjugated chitosan nanoparticles	73
3.5.5	Evaluation of Entrapment efficiency and <i>in vitro</i> drug release.....	79
3.5.6	Cellular uptake analysis	80
3.5.7	Cytotoxicity study	83
3.5.8	Tissue bio-distribution study.....	83
3.5.9	<i>In vivo</i> fluorescent bio-imaging	84
3.5.10	Histopathological Observation.....	85

3.5.11	Induction of Lung cancer	86
3.5.12	<i>In vivo</i> anticancer efficacy	87
3.6	Conclusion	89
4	EGFR and glycan receptor targeted chitosan nanoparticles for enhanced active cellular internalization of gemcitabine in lung cancer therapy	91
4.1	Objective	91
4.2	Plan of study	91
4.3	Material	92
4.4	Methods.....	93
4.4.1	Optimization of chimeric mAb conjugated chitosan nanoparticles	93
4.4.2	Preparation of gemcitabine loaded targeted and non-targeted chitosan nanoparticles	94
4.4.3	Characterization of nanoformulations.....	96
4.4.4	<i>In vitro</i> studies.....	100
4.4.5	<i>In vivo</i> studies	103
4.5	Results and discussion	105
4.5.1	Optimization of chimeric mAb conjugated chitosan nanoparticles	105
4.5.2	Physiochemical characterization of nanoparticles	106
4.5.3	Determination of entrapment efficiency (% EE)	108
4.5.4	Morphological analysis of nanoparticles	108
4.5.5	Evaluation of surface chemistry of nanoparticles	110
4.5.6	Solid state characterization of nanoparticles.....	110
4.5.7	Estimation of amount of 5-N-acetyl-neuraminic acid conjugated in CSN-Neu5AC conjugate and on to surface of nanoparticles	113
4.5.8	Estimation of cetuximab concentration conjugated on surface of nanoparticles	113
4.5.9	<i>In vitro</i> studies.....	113
4.5.10	<i>In vivo</i> evaluation.....	124
4.6	Discussion and Conclusion	128
5	Summary and Future prospective	134
5.1	Summary	134
5.2	Future research perspectives	136
6	References:.....	137
7	Publications	158
7.1	Publication from Research Work.....	158
7.2	Other Publications.....	158
7.3	Book Chapters.....	159
8	Curriculum Vitae	160